European Thyroid Journal最新文献_第8页

Development of an enzyme-linked immunosorbent assay for newborns dried blood spot thyroglobulin. 为新生儿干血斑甲状腺球蛋白开发酶联免疫吸附试验。

IF 3.5 2区医学

European Thyroid Journal Pub Date : 2024-11-25 Print Date: 2024-12-01 DOI: 10.1530/ETJ-24-0142

Camilo Fuentes Peña, María Cecilia Opazo, Luis Méndez, Claudia Riedel, Bernard Hauquier, Lionel Marcelis, Frédéric Cotton, Rodrigo Moreno-Reyes

{"title":"Development of an enzyme-linked immunosorbent assay for newborns dried blood spot thyroglobulin.","authors":"Camilo Fuentes Peña, María Cecilia Opazo, Luis Méndez, Claudia Riedel, Bernard Hauquier, Lionel Marcelis, Frédéric Cotton, Rodrigo Moreno-Reyes","doi":"10.1530/ETJ-24-0142","DOIUrl":"10.1530/ETJ-24-0142","url":null,"abstract":"Background: Thyroglobulin (Tg) is a biomarker of iodine status. Newborn Tg is a more sensitive marker than neonatal TSH in detecting variations in iodine intake. This study aims to validate an enzyme-linked immunosorbent assay (ELISA) for Tg determination on dried blood spots (DBS) in newborns. This study also sets out to assess the stability of Tg and the influence of newborns' hematocrit on Tg determination.Methods: A commercially available ELISA Tg assay was adapted for use on DBS. DBS-Tg in cord blood was measured in 209 newborns delivered from healthy euthyroid pregnant women. Sensitivity, linearity, repeatability, and intermediate fidelity were determined using the appropriate standards and quality control materials.Results: The limit of detection of the DBS-Tg assay was 2.4 µg/L, and the limit of quantification was 5.8 µg/L. Repeatability and intermediate fidelity were 7.7-8.3% and 11.0-11.2%, respectively. The median cord plasma Tg and DBS-Tg values in newborns were not significantly different, 30.2 (21.3-44.4) µg/L and 31.6 (19.3-48.7) µg/L (P = 0.48) with the ELISA, respectively, and 76.5 (40.0-101.5) µg/L with the Elecsys assay with an R = 0.88. DBS-Tg concentrations decrease with increasing hematocrit values (P < 0.05). DBS-Tg values were stable at a concentration of 25 µg/L for 12 months at -20ºC and 4ºC.Conclusion: This DBS-Tg assay demonstrated good analytical performance over a wide range of Tg concentrations, suggesting it is well suited to detecting variations in Tg concentrations. Studies comparing populations with different prevalence of anemia should consider the effect of hematocrit on DBS-Tg determination. The availability of a DBS-Tg assay for newborns makes it possible to integrate iodine status monitoring with newborn screening for inherited metabolic diseases.","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623250/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142562694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Toward a treatment for thyroid hormone transporter MCT8 deficiency - achievements and challenges. 治疗甲状腺激素转运体 MCT8 缺乏症：成就与挑战。

IF 3.5 2区医学

European Thyroid Journal Pub Date : 2024-11-20 Print Date: 2024-12-01 DOI: 10.1530/ETJ-24-0286

Boyka Markova, Steffen Mayerl, Heike Heuer

引用次数: 0

Real world outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma. 卡博替尼治疗分化不良甲状腺癌的真实疗效。

IF 3.5 2区医学

European Thyroid Journal Pub Date : 2024-11-20 Print Date: 2024-12-01 DOI: 10.1530/ETJ-24-0225

Omar Elghawy, Adam Barsouk, Jessica Xu, Simon Chen, Roger B Cohen, Lova Sun

{"title":"Real world outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma.","authors":"Omar Elghawy, Adam Barsouk, Jessica Xu, Simon Chen, Roger B Cohen, Lova Sun","doi":"10.1530/ETJ-24-0225","DOIUrl":"10.1530/ETJ-24-0225","url":null,"abstract":"Objective: Poorly differentiated thyroid carcinomas (PDTCs) are rare and aggressive head and neck malignancies with a poor prognosis. Systemic treatment for incurable PDTC consists of multi-kinase inhibitors (MKIs) based on extrapolation from the experience with radioiodine refractory differentiated thyroid cancer (DTC). Cabozantinib is an approved second-line MKI therapy for DTC, but there are limited data regarding the safety and efficacy of cabozantinib for PDTC.Methods: We conducted a single-institution, retrospective analysis of patients with PDTC who received cabozantinib in any line of therapy. Baseline demographics, disease characteristics, treatment history, toxicity, and clinical outcomes were abstracted from the electronic medical record. Median progression-free survival (PFS) and overall survival (OS) were primary endpoints and estimated using Kaplan-Meier methodology.Results: Seven patients with PDTC who received cabozantinib were included. 4/7 (57%) patients had a partial response to cabozantinib, while 2/7 (29%) had stable disease (SD) as their best response. The median time on treatment for cabozantinib was 10.53 months. The median PFS from the start of cabozantinib was 12.9 months, and median OS was 14.21 months. Most adverse events to treatment (5/6) were low grade. Two (29%) patients were alive at the date of the last follow-up.Conclusion: Cabozantinib is an effective and reasonably well-tolerated treatment option for patients with PDTC. Prospective studies are needed to further investigate the role of cabozantinib in the treatment of PDTC, alone and in combination with other agents, including checkpoint inhibitors.","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142562698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thyrotoxic periodic paralysis - a retrospective study from Southern India. 甲亢性周期性麻痹--来自印度南部的回顾性研究。

IF 3.5 2区医学

European Thyroid Journal Pub Date : 2024-11-11 Print Date: 2024-12-01 DOI: 10.1530/ETJ-24-0164

Jinson Paul, Aneez Joseph, Felix Jebasingh, Atul Ramachandra More, Julie Hephzibah, Kripa Elizabeth Cherian, Nitin Kapoor, Hesarghatta Shyamsunder Asha, Nihal Thomas

{"title":"Thyrotoxic periodic paralysis - a retrospective study from Southern India.","authors":"Jinson Paul, Aneez Joseph, Felix Jebasingh, Atul Ramachandra More, Julie Hephzibah, Kripa Elizabeth Cherian, Nitin Kapoor, Hesarghatta Shyamsunder Asha, Nihal Thomas","doi":"10.1530/ETJ-24-0164","DOIUrl":"10.1530/ETJ-24-0164","url":null,"abstract":"Objective: Thyrotoxic periodic paralysis is a rare manifestation of thyrotoxicosis. Here, we describe the clinical and biochemical features and treatment outcomes of this disorder.Methods: This retrospective study was conducted at a tertiary care centre in southern India. The clinical and biochemical features, treatment received, and therapeutic outcomes of all patients with thyrotoxicosis and acute flaccid paralysis without any other identifiable causes (cases for the study) were compared with an equal number of consecutively selected patients who presented with thyrotoxicosis but without features of paralysis (controls for the study) during the same period.Results: In total, 41 cases and controls were included in this study. The proportion of males was 92.6% and 43.9% in the cases and controls, respectively. The mean age was 32.8 (±7.6) years (cases) and 39.7 (±11.3) years (controls). In the cases, 20% of patients presented without clinical thyrotoxic features. Graves' disease was the most common aetiology of thyrotoxicosis in both groups (92.6% of cases and 87.8% of controls). The prevalence of goitre was significantly higher among controls (90.2%) than among cases (53.7%). The mean serum potassium, free T4, total T4 and total T3 levels were significantly lower in the cases than in the controls. In these cases, two patients had an additional aetiology for persistent hypokalaemia, likely Gitelman's syndrome.Conclusion: This is one of the largest series of thyrotoxic periodic paralysis cases in India. In subjects with thyrotoxicosis, serum potassium, free T4, total T4 and total T3 levels were significantly lower in those with periodic paralysis than in those without.","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of iodine contrast media on thyroid function - a prospective study. 碘造影剂对甲状腺功能的影响--一项前瞻性研究。

IF 3.5 2区医学

European Thyroid Journal Pub Date : 2024-11-11 Print Date: 2024-12-01 DOI: 10.1530/ETJ-24-0244

Jeanette Carlqvist, Ulf Nyman, John Brandberg, Helena Filipsson Nyström, Mikael Hellström

{"title":"Effects of iodine contrast media on thyroid function - a prospective study.","authors":"Jeanette Carlqvist, Ulf Nyman, John Brandberg, Helena Filipsson Nyström, Mikael Hellström","doi":"10.1530/ETJ-24-0244","DOIUrl":"10.1530/ETJ-24-0244","url":null,"abstract":"Objectives: When exposed to iodine contrast medium (ICM), thyroid dysfunction may develop, due to excess amounts of iodide. The incidence of contrast-induced thyroid dysfunction has been difficult to interpret, because of the observational and retrospective designs of most previous studies. With the Swedish CArdioPulmonary bioImage Study (SCAPIS), where randomly selected individuals aged 50-65 years, underwent contrast-enhanced coronary CT angiography (CCTA), we were able to prospectively assess the incidence, magnitude and clinical impact of contrast-induced thyroid dysfunction.Methods: In 422 individuals, thyroid hormone levels were analysed before and 4-12 weeks after CCTA. Thyroid-related patient-reported outcome questionnaires (ThyPRO) at the time of pre and post-CCTA blood samplings were provided by 368 of those individuals. Thyroid peroxidase antibodies (TPOab) were analysed and an ultrasound of the thyroid gland was performed to detect any thyroid nodules.Results: There was a small statistically significant effect on thyroid hormone levels but no cases of overt hypo- or hyperthyroidism after ICM. Subclinical hypo- or hyperthyroidism or isolated low/high levels of free thyroxine (fT4) developed in 3.5% of the population with normal hormone levels pre-CCTA but without any increased thyroid-related symptoms compared to the remaining cohort. Elevated TPOab and being born outside Sweden were risk factors for developing subclinical hypothyroidism. The presence of thyroid nodules was not associated with ICM-induced thyroid dysfunction.Conclusion: The results of this prospective study support the notion that in iodine-sufficient countries, ICM-associated thyroid dysfunction is rare, usually mild, self-limiting and oligo/asymptomatic in subjects aged 50-65 years.","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623283/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Graves' hyperthyroidism treated with potassium iodide: early response and after 2 years of follow-up. 用碘化钾治疗巴塞杜氏甲状腺功能亢进症：早期反应和两年随访。

IF 3.5 2区医学

European Thyroid Journal Pub Date : 2024-11-08 Print Date: 2024-12-01 DOI: 10.1530/ETJ-24-0085

Megumi Fujikawa, Ken Okamura

{"title":"Graves' hyperthyroidism treated with potassium iodide: early response and after 2 years of follow-up.","authors":"Megumi Fujikawa, Ken Okamura","doi":"10.1530/ETJ-24-0085","DOIUrl":"10.1530/ETJ-24-0085","url":null,"abstract":"Objective: As thionamide is associated with various adverse effects, we re-evaluated the practical efficacy of potassium iodide (KI) therapy for Graves' hyperthyroidism (GD).Methods: We administered KI (mainly 100 mg/day) to 324 untreated GD patients and added methimazole (MMI) only to those remaining thyrotoxic even at 200 mg/day. When the patient became hypothyroid, MMI, if taken was stopped, then levothyroxine (LT4) was added without reducing the KI dose. Radioactive iodine (RI) therapy or thyroidectomy was performed whenever required. We evaluated the early effects of KI at 2-4 weeks and followed patients for 2 years.Results: At 2 weeks, serum thyroid hormone levels decreased in all 324 patients. At 4 weeks, fT4, fT3, and both fT4 and fT3 levels became normal or low in 74.7%, 50.6%, and 50.6% of patients, respectively. In a cross-sectional survey over 2 years, GD was well-controlled with KI or KI + LT4 (KI-effective) in >50% of patients at all time points. Among 288 patients followed for 2 years, 42.7% remained 'KI-effective' throughout the 2 years (KI Group), 30.9% were well-controlled with additional MMI given for 1-24 months, and 26.4% were successfully treated with ablative therapy (mainly RI). Among 'KI-effective' patients at 4 weeks, 76.5% were classified into the KI Group. No patients experienced adverse effects from KI.Conclusion: KI therapy was useful in the treatment of GD. A sufficient dose of KI was effective in >50% of GD patients from 4 weeks to 2 years, and 42.7% (76.5% of 'KI-effective' patients at 4 weeks) remained 'KI-effective' throughout the 2 years.","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Echogenicity as a standalone nodule characteristic is not inferior to the TIRADS systems in the 10-20 mm nodule diameter range in patient selection for fine needle aspiration: a pilot study. 在选择患者进行细针穿刺时，在结节直径为 10 至 20 毫米的范围内，作为独立结节特征的回声不劣于 TIRADS 系统；一项试点研究。

IF 3.5 2区医学

European Thyroid Journal Pub Date : 2024-11-06 Print Date: 2024-12-01 DOI: 10.1530/ETJ-24-0149

Karoly Rucz, Laszlo Hegedűs, Steen Joop Bonnema, Andrea Frasoldati, Laszlo Jambor, Gabor Laszlo Kovacs, Enrico Papini, Gilles Russ, Zsolt Karanyi, Endre V Nagy, Tamas Solymosi

{"title":"Echogenicity as a standalone nodule characteristic is not inferior to the TIRADS systems in the 10-20 mm nodule diameter range in patient selection for fine needle aspiration: a pilot study.","authors":"Karoly Rucz, Laszlo Hegedűs, Steen Joop Bonnema, Andrea Frasoldati, Laszlo Jambor, Gabor Laszlo Kovacs, Enrico Papini, Gilles Russ, Zsolt Karanyi, Endre V Nagy, Tamas Solymosi","doi":"10.1530/ETJ-24-0149","DOIUrl":"10.1530/ETJ-24-0149","url":null,"abstract":"Objective: The ultrasound evaluation of thyroid nodules (TNs) in patient selection for fine needle aspiration (FNA) requires both uniformly accepted definitions of each nodule characteristic and extensive experience from the examiner. We hypothesized that nodule echogenicity alone may provide comparable performance to more complex approaches in patient selection for FNA.Patients and methods: Seven highly experienced investigators from four countries evaluated, online, the ultrasound (US) video recordings of 123 histologically verified TN by answering 17 nodule characteristics-related questions. The diagnostic performances of five TN image reporting and data systems (TIRADS) were compared to making decisions based solely on the echogenicity of the nodule for indicating FNA in 110 nodules ≥10 mm.Results: In the 10-20 mm size range, the sensitivities and specificities of the five TIRADS systems in identifying malignant nodules were 80.5-91.0% and 31.4-50.9%, respectively. Had FNA been recommended for all hypoechoic nodules, disregarding other US characteristics, comparable sensitivity and specificity (87.5% and 43.4%, respectively) were obtained. Compared to nodules >20 mm, a higher proportion of cancers were hypoechoic in the 10-20 mm size range (87.2% vs 77.8%, P = 0.05). In the 10-20 mm size range, compared to hypoechoic nodules, a significantly lower proportion of isoechoic nodules demonstrated suspicious findings (70.7% vs 30.0%, P < 0.05).Conclusion: In contrast to >20 mm diameter nodules, the recommendation of FNA may rely on a single US feature, echogenicity, in the 10-20 mm size range. If independently confirmed in larger cohorts, this may simplify nodule evaluation in this size range.","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142389197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of genetics and epigenetics in Graves' orbitopathy. 遗传学和表观遗传学在巴塞杜氏眶病中的作用。

IF 3.5 2区医学

European Thyroid Journal Pub Date : 2024-11-06 Print Date: 2024-12-01 DOI: 10.1530/ETJ-24-0179

Michele Marinò, Giovanna Rotondo Dottore, Francesca Menconi, Simone Comi, Giada Cosentino, Roberto Rocchi, Francesco Latrofa, Michele Figus, Ferruccio Santini

{"title":"Role of genetics and epigenetics in Graves' orbitopathy.","authors":"Michele Marinò, Giovanna Rotondo Dottore, Francesca Menconi, Simone Comi, Giada Cosentino, Roberto Rocchi, Francesco Latrofa, Michele Figus, Ferruccio Santini","doi":"10.1530/ETJ-24-0179","DOIUrl":"10.1530/ETJ-24-0179","url":null,"abstract":"Objectives: The pathogenesis of Graves' orbitopathy (GO) remains to be fully elucidated. Here, we reviewed the role of genetics and epigenetics.Design: We conducted a PubMed search with the following keywords: GO, thyroid eye disease; or Graves' ophthalmopathy; or thyroid-associated ophthalmopathy; and: genetic, or epigenetic, or gene expression, or gene mutation, or gene variant, or gene polymorphism, or DNA methylation, or DNA acetylation. Articles in which whole DNA and/or RNA sequencing, proteome, and methylome analyses were performed were chosen.Results: The different prevalence of GO in the two sexes, as well as racial differences, suggest that genetics play a role in GO pathogenesis. In addition, the long-lasting phenotype of GO and patient-derived orbital fibroblasts suggests a genetic or epigenetic mechanism. Although no genes have been found to confer a specific risk for GO, differential gene expression has been reported in orbital fibroblasts from GO patients vs control fibroblasts, suggesting that an epigenetic mechanism may be involved. In this regard, a different degree of DNA methylation, which affects gene expression, has been found between GO and control fibroblasts, which was confirmed by whole methylome analysis. Histone acetylation and deacetylation, which also affect gene expression, remain to be investigated.Conclusions: Although no pathogenic gene variants have been reported, epigenetic mechanisms elicited by an initial autoimmune insult seem to be needed for differential gene expression to occur and, thus, for GO to develop and persist over time.","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142389198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence and gender difference of brain metastases in newly diagnosed follicular thyroid cancer patients. 新确诊滤泡型甲状腺癌患者脑转移的发生率和性别差异

IF 3.5 2区医学

European Thyroid Journal Pub Date : 2024-11-01 DOI: 10.1530/ETJ-24-0093

Ruiguo Zhang, Weijian Li, Hui Wang, Wenxin Zhang, Jinyan Chai, Pengpeng Chang, Qiang Jia, Wei Zheng

{"title":"Incidence and gender difference of brain metastases in newly diagnosed follicular thyroid cancer patients.","authors":"Ruiguo Zhang, Weijian Li, Hui Wang, Wenxin Zhang, Jinyan Chai, Pengpeng Chang, Qiang Jia, Wei Zheng","doi":"10.1530/ETJ-24-0093","DOIUrl":"10.1530/ETJ-24-0093","url":null,"abstract":"Background: Population-based estimates of brain metastases in follicular thyroid cancer (FTC) patients with or without distant metastases (DMs) at diagnosis are lacking.Objective: To study the prevalence of brain metastases in FTC patients and compare gender disparity.Methods: DMs are defined as bone, lung, and brain metastases. Using the SEER database, we identified 5116 patients diagnosed with FTC between 2010 and 2019. The incidences of brain metastases were calculated for the entire cohort and among patients with bone/lung metastases. Cohorts were stratified by gender and age.Results: 4.8% (245) had DMs at diagnosis, primarily in the form of bone metastases (3.6%), followed by lung metastases (2.4%). The incidence of brain metastases at initial diagnosis was only 0.37% (17 females and 2 males), but occurred in 8.2% and 6.1% of patients with bone metastases and lung metastases, respectively. Median survival for patients with brain metastases was only 8.0 months (95% CI, 4.1-11.9). Interestingly, female patients with bone metastases exhibited a significantly higher incidence of brain metastases compared to males (12.0% vs. 1.5%), with a notable odds ratio of 8.971 (95% CI:1.152-69.835) in univariate analysis. Multivariate logistic regression analysis confirmed that being female (odds ratio, 10.08; 95% CI:1.243-81.748) was the sole statistically significant risk factor for brain metastases in FTC patients with bone metastases at diagnosis.Conclusion: An incidence of brain metastases is observed in newly diagnosed FTC patients with DMs, especially in females with bone involvement. Our findings advocate for the early detection of brain metastases in female FTC patients with concurrent bone metastases at diagnosis.","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11737522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IgG4 glycosylation contributes to the pathogenesis of IgG4 Hashimoto's thyroiditis via the complement pathway. IgG4 糖基化通过补体途径促进了 IgG4 桥本氏甲状腺炎的发病机制。

IF 3.5 2区医学

European Thyroid Journal Pub Date : 2024-10-24 Print Date: 2024-10-01 DOI: 10.1530/ETJ-24-0156

Chenxu Zhao, Zhiming Sun, Shuaihang Wang, Jixin Zhang, Jumei Liu, Lei Chen, Guizhi Lu, Yang Yu, Ying Gao

{"title":"IgG4 glycosylation contributes to the pathogenesis of IgG4 Hashimoto's thyroiditis via the complement pathway.","authors":"Chenxu Zhao, Zhiming Sun, Shuaihang Wang, Jixin Zhang, Jumei Liu, Lei Chen, Guizhi Lu, Yang Yu, Ying Gao","doi":"10.1530/ETJ-24-0156","DOIUrl":"10.1530/ETJ-24-0156","url":null,"abstract":"Background: To explore whether IgG4 is involved in the pathogenesis of IgG4 HT.Methods: Serum TgAb IgG4 and TPOAb IgG4 were measured in IgG4 HT and non-IgG4 HT. C1q, mannose-binding lectin (MBL), Bb, C3d, C4d, and membrane attack complex (MAC) in thyroid tissues from IgG4 HT, non-IgG4 HT, and controls were examined by immunohistochemistry. We assessed IgG4 and MAC deposition in mouse thyroid by immunohistochemistry after injecting purified IgG4 into mice. The glycosylation patterns of TgAb IgG4 from IgG4 HT were identified by MALDI-TOF-MS. The ability of IgG4 to bind to MBL before and after deglycosylation was assessed by ELISA. MBL and MAC fluorescence were detected in thyrocytes after the addition of IgG4 or deglycosylated IgG4.Results: Serum TgAb IgG4 and TPOAb IgG4 levels were significantly higher in the IgG4 HT group. MBL, Bb, C3d, C4d, and MAC levels were significantly higher in the thyroid tissues of IgG4 HT than in non-IgG4 HT (all P < 0.001). IgG4 colocalized with MBL by immunofluorescence. In mice, follicular cell structure disruption was observed after the injection of IgG4 from IgG4 HT, as well as the colocalization of IgG4 with MAC. High levels of TgAb IgG4 glycosylation patterns, including monogalactose glycan (G1F), galactose-deficient glycan (G0F), and high-mannose glycan (M5), were detected in IgG4 HT. After deglycosylation, IgG4 reduced its ability to bind to MBL, and there was low MBL and MAC activation in thyrocytes.Conclusion: High levels of IgG4 glycosylation patterns, including G1F, G0F, and M5, may activate the complement lectin pathway, thereby participating in the pathogenesis of IgG4 HT.","PeriodicalId":12159,"journal":{"name":"European Thyroid Journal","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0